Finally, findings from our study shed new light on the beneficial effects and mechanisms of targeting human TNFR2 with human-specific compounds and the suitability of NewStar2 as potential new therapeutic for AD. The gene discussed is TNFRSF1B; the disease is Alzheimer disease.